296 related articles for article (PubMed ID: 14871963)
1. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
2. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
4. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
5. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
[TBL] [Abstract][Full Text] [Related]
7. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Cheng CL; Johnson SP; Keir ST; Quinn JA; Ali-Osman F; Szabo C; Li H; Salzman AL; Dolan ME; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2005 Sep; 4(9):1364-8. PubMed ID: 16170028
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
12. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
13. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
[TBL] [Abstract][Full Text] [Related]
14. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
[TBL] [Abstract][Full Text] [Related]
15. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
Tentori L; Turriziani M; Franco D; Serafino A; Levati L; Roy R; Bonmassar E; Graziani G
Leukemia; 1999 Jun; 13(6):901-9. PubMed ID: 10360379
[TBL] [Abstract][Full Text] [Related]
16. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
[TBL] [Abstract][Full Text] [Related]
18. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
20. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
